Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/medecine/imaging-methodology-and-applications-in-parkinson-s-disease/descriptif_3785675
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3785675

Imaging in Movement Disorders Imaging Methodology and Applications in Parkinson's Disease

Langue : Anglais
Couverture de l’ouvrage Imaging in Movement Disorders

Imaging Methodology and Applications in Parkinson's Disease, Volume 141, provides an up-to-date and comprehensive textbook on the use of imaging modalities across the spectrum of movement disorders and dementias. Over the last decades, advances in neuroimaging tools has played a pivotal role in expanding our understanding of disease etiology and pathophysiology, identifying biomarkers to monitor disease progression, aiding differential diagnosis, and in the identification of novel targets for therapeutic intervention. This book brings together lessons learned from neuroimaging tools in movement disorders, including chapters on Advances in PET Methodology, Advances in MRI Methodology, Advances in SPECT Methodology, Hybrid PET/MRI Methodology, and more.

Section 1: Imaging Methodology 1. Advances in PET Methodology Vesna Sossi 2. Advances in MRI Methodology Tayyabah Yousaf, George Dervenoulas and Marios Politis 3. Advances in SPECT Methodology Alberto Cuocolo, Sabina Pappatà, Emilia Zampella and Roberta Assante 4. Hybrid PET/MRI Methodology Marco Aiello, Carlo Cavaliere, Rocco Marchitelli, Antonio d'Albore, Enrico De Vita and Marco Salvatore

Section 2: Imaging Applications in Parkinson's Disease 5. Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson’s Disease Edoardo R. de Natale, Flavia Niccolini, Heather Wilson and Marios Politis 6. Molecular Imaging of the Serotonergic System in Parkinson’s Disease Gennaro Pagano and Marios Politis 7. Molecular Imaging of the Cholinergic System in Parkinson’s Disease Nicolaas I. Bohnen, Prabesh Kanel and Martijn L.T.M. Müller 8. Molecular Imaging of the Noradrenergic System in Idiopathic Parkinson's Disease Adjmal Nahimi, Martin B. Kinnerup, Michael Sommerauer, Albert Gjedde and Per Borghammer 9. Molecular Imaging of Opioid System in Idiopathic Parkinson’s Disease S. Thobois, C. Brefel-Courbon, D. Le Bars and V. Sgambato 10. Molecular Imaging of the Cannabinoid System in Idiopathic Parkinson’s Disease Roberto Cilia 11. Molecular Imaging of Neuroinflammation in Idiopathic Parkinson’s Disease Andreas-Antonios Roussakis and Paola Piccini 12. Molecular Imaging of Addictive Behavior in Idiopathic Parkinson's Disease Christine Ghadery, Mikaeel Valli, Alexander Mihaescu, Rebecca Strafella, Irene Navalpotro, Jinhee Kim and Antonio P. Strafella 13. Structural MRI in Idiopathic Parkinson’s Disease Rosa De Micco, Antonio Russo and Alessandro Tessitore 14. Functional MRI in Idiopathic Parkinson's Disease Massimo Filippi, Sarasso Elisabetta, Noemi Piramide and Federica Agosta

  • Provides an up-to-date and comprehensive textbook addressing all aspects of neuroimaging in movement disorders
  • Offers a complete review of advances in core imaging methodology and the application of neuroimaging tools
  • Represents an indispensable educational and research reference of value to all movement disorder specialists, physicians, researchers and students

Date de parution :

Ouvrage de 485 p.

15x22.8 cm

Disponible chez l'éditeur (délai d'approvisionnement : 14 jours).

166,19 €

Ajouter au panier

Thèmes d’Imaging in Movement Disorders :

Mots-clés :

[11C]CAF (carfentanil); [11C]DPN (diprenorphine); Acetylcholine; Activated state; Addiction; Addictions; Addictive behavior; Adrenoceptors; Anatomical MRI; Arterial input function; Arterial spin labeling; Astrocytes; Attenuation correction; Bimodal probes; Brain network; Cannabinoids; Cerebral blood flow; Cognition; Cognitive deficits; Connectivity; DASB; Dementia with Lewy bodies; Depression; Diffusion tensor imaging; Dopamine; Dopamine dysregulation syndrome; Dopamine replacement therapy; Dopaminergic system; Dyskinesias; Eating disorders; Endocannabinoid system; Functional and metabolic networks; Functional connectivity; Functional MRI; Gait; Gray matter; Hybrid imaging; I2BS; Imaging; Impulse control disorders; Magnetic resonance; Magnetic resonance imaging; Malignant phenotype; Microglia; Molecular imaging; Motion correction; Motor; Motor symptoms; MRI; Neurodegeneration; Neuroinflammation; Neuromelanin-sensitive MR; Neuropsychiatric manifestations; Nonmotor symptoms; Non-motor symptoms; Noradrenaline; Noradrenaline transporter; Pain; Parkinson; Parkinson's disease; Partial volume correction; PET; PET data processing and analysis; Pharmacokinetic modeling; Positron emission tomography; Preclinical PET/MR; Quantitative molecular and multi-modal imaging; Quantitative susceptibility mapping; Receptor imaging; Reconstruction algorithm; Resting state; Resting-state functional MRI; Semiquantitative analysis; Serotonin; Single-photon emission computed tomography; Sleep; SPECT; Susceptibility weighted imaging; Task; The addiction circuitry; Translocator protein; Tremor; White matter